Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 381

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 381
---
 Diagnostics, we utilize Genoox’s medical genetics platform Franklin to enable more personalized and targeted therapies. Customer Concentration and Revenue Trends We rely on commercial partnerships, such as our relationship with CIBIC, which provides for a significant part of our revenue and accounted for 93.5% and 96.6% of revenues for the years ended June 30, 2024 and 2023, respectively. CIBIC is the exclusive distributor in Argentina for our diagnostic tests. This allows the use of CIBIC’s commercial channels in a business -to -businessmodel, as other CIBIC products complement our product offerings in Argentina. This model does not apply to Rewell, where CIBIC neither distributes the product nor holds exclusivity over it, functioning in an open business -to -businessand business to consumer (direct -to -consumer) model. As this product grows, dependence on CIBIC will decrease. Additionally, CIBIC will not participate in sales of our Heritas Diagnostic and Rewell products in countries other than Argentina. Other funding sources will include: Rewell in Argentina (business to consumer or business -to -business); Diagnostics and Rewell in other countries. The distribution model reduces the risks associated with product market entry (both commercial and regulatory) in each country and, in parallel, allows exclusive distribution to be anchored to a business plan that the distributor must meet, minimizing the initial risk of operations in each country. In addition, we receive payments from a variety of sources, including patients, biopharmaceutical partners, third -partypayers, and other business -to -businesscustomers. We rely on sales that occur through private channels and from social security. We believe that our performance and future success depends on several factors that present significant opportunities for growth but also pose risks and challenges, including those in the section of this proxy statement/prospectus entitled “ Risk Factors — Risks Related to Our Business and Industry.” Human Capital Resources People and Diversity The strength of our team and the culture in which they work is essential to our ability to achieve our broader mission. As such, we seek to attract and retain top tier talent and provide them the opportunity to develop along with the company. Our human capital is dedicated to enhancing individual development and nurturing a culture of collaboration and unity within our teams. We foster a community filled with people from various disciplines, including science, medicine, data science, entrepreneurship, business, marketing, and sales. This multifaceted team is not only diverse in expertise but